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Acetylation of C/EBPa inhibits its granulopoietic
function
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CCAAT/enhancer-binding protein alpha (C/EBPa) is an essential transcription factor for
myeloid lineage commitment. Here we demonstrate that acetylation of C/EBPa at lysine
residues K298 and K302, mediated at least in part by general control non-derepressible
5 (GCN5), impairs C/EBPa DNA-binding ability and modulates C/EBPa transcriptional
activity. Acetylated C/EBPa is enriched in human myeloid leukaemia cell lines and acute
myeloid leukaemia (AML) samples, and downregulated upon granulocyte-colony stimulating
factor (G-CSF)- mediated granulocytic differentiation of 32Dcl3 cells. C/EBPa mutants that
mimic acetylation failed to induce granulocytic differentiation in C/EBPa-dependent assays,
in both cell lines and in primary hematopoietic cells. Our data uncover GCN5 as a negative
regulator of C/EBPa and demonstrate the importance of C/EBPa acetylation in myeloid
differentiation.
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H
ematopoiesis is a precisely controlled process involving
differentiation of multipotential hematopoietic stem cells
(HSCs) into specific lineages, regulated by transcription
factors. CCAAT/enhancer-binding protein alpha (C/EBPa) is one
of the transcription factors that is crucial for both myeloid
differentiation and maintenance of quiescence in adult HSCs.
The role of C/EBPa in granulopoiesis is demonstrated through
Mx1-Cre-driven conditional disruption of C/EBPa in adult mice,
resulting in a differentiation block during the transition from
common myeloid progenitors to granulocyte monocyte
progenitors and increased HSC self-renewal1,2. Moreover,
expression of C/EBPa in both leukaemic cell lines and in human
CD34þ -enriched HSCs lead to granulocytic differentiation3–5.
Changes in C/EBPa expression and function are associated
with impaired myeloid lineage fate decisions while dysregulation
of C/EBPa function is frequently associated with
leukaemogenesis6–10. Acetylation catalysed by lysine acetyl-
transferases (KATs) is an important post-translational
modification (PTM), and KATs play pivotal roles in numerous
cellular processes. More importantly, histones are not the
only physiological acetylation targets11. C/EBPa involvement
with KATs has been previously reported12–15, but the role of
acetylation in modulating C/EBPa function has not been
addressed.
In this study, we identify the ability of KAT GCN5 to interact
and acetylate C/EBPa on at least lysine K298 and K302 in the
basic DNA-binding domain (DBD), which results in impaired
DNA-binding activity. Moreover, wild-type (WT) GCN5 but not
the mutant, catalytically inactive GCN5 represses C/EBPa
transactivation and short hairpin RNA (shRNA) knockdown of
GCN5 results in upregulation of C/EBPa activity. C/EBPa
acetylation is detectable in myeloid cell lines, primary leukaemic
samples and drops dramatically during granulocytic
differentiation of 32Dcl3 cells on granulocyte-colony stimulating
factor (G-CSF) treatment. An acetylation mimetic mutant of
C/EBPa shows loss of DNA binding resulting in the loss of
transcriptional activity as predicted by molecular dynamics
(MD) simulations. Our study is the first to provide an
understanding of how C/EBPa activity is regulated by KAT at
the post-translational level.
Results
C/EBPa is acetylated in its C-terminal region by GCN5. Given
C/EBPa expression normally triggers differentiation of immature
myeloblasts into mature granulocytes, we investigated why some
leukaemic cell lines remain undifferentiated despite high levels
of expression of non-mutated C/EBPa. One possibility is the
inactivation of WT C/EBPa protein by PTM. Therefore, we
investigated whether acetylation is a negative regulator of C/EBPa
activity. Using a pan-acetyl-lysine antibody, acetylated C/EBPa was
detected in leukaemic cell lines HL-60 and Molm-14 (Fig. 1a).
Next, we sought to investigate which acetyltransferase/s represses
C/EBPa activity. A C/EBPa-dependent promoter-luciferase
reporter construct was used to measure the transcriptional activity
of C/EBPa. Co-transfection of various acetyltransferases with a
C/EBPa expression plasmid was performed in 293T cells lacking
endogenous C/EBPa. Among the acetyltransferases tested, GCN5
was found to repress C/EBPa transcriptional activity (Fig. 1b). Co-
transfection of p300 and C/EBPa resulted in an increase in the
C/EBPa transactivation activity as previously reported (Supple-
mentary Fig. 1a)14. Co-transfection of GCN5 antagonized the
ability of C/EBPa to activate the reporter plasmid in a dose-
dependent manner, without affecting C/EBPa protein levels
(Fig. 1b, Supplementary Fig. 1a–c). GCN5 alone had no effect on
luciferase activity, indicating that GCN5 specifically mediates
downregulation of the reporter through interaction with C/EBPa
(Fig. 1b). Expression of these acetyltransferases and
C/EBPa were confirmed by using western blot (Supplementary
Fig. 1b). A co-immunoprecipitation experiment showed both
GCN5 and PCAF (p300/CBP associated factor, a GCN5
homologue) interact with C/EBPa (Supplementary Fig. 1d). To
address the question whether acetyltransferase activity of GCN5 is
required to repress C/EBPa transcriptional activity, an
acetyltransferase-defective mutation of GCN5 (-HAT, Y621A/
P622A) was used in place of WT GCN5 (ref. 16). Indeed, the
mutated HAT-deficient form failed to repress C/EBPa
transcriptional activity, indicating that acetyltransferase activity is
essential for repression (Fig. 1c, Supplementary Fig. 1c). In a
reciprocal experiment, C/EBPa transcriptional activity doubled
when endogenous GCN5 was efficiently knocked down (shGCN5
# 3; Fig. 1d,e). Taken together, our data indicate that GCN5
inhibits C/EBPa transactivation in an acetyltransferase-dependent
manner, although the role of other HATs in this process cannot be
excluded.
Subsequently, we performed an in vitro acetyltransferase assay
using GCN5 and C/EBPa peptides. K298, K302 and K326
were identified as the sites of acetylation by GCN5 (Fig. 1f,
Supplementary Fig. 1e–g and Supplementary Table 1). These
lysine residues have high degree of evolutionary conservation
across different species, suggesting crucial role for C/EBPa
function (Supplementary Fig. 1h). K298 and K302 are exposed on
the basic DBD, whereas K326 resides in the leucine zipper
dimerization domain (Fig. 1g)17,18.
To further investigate the protein domains involved in the
C/EBPa–GCN5 interaction, we performed co-immunoprecipita-
tion assays in 293T cells (Supplementary Fig. 1i). While
immunoblot analysis using FLAG and V5 antibodies revealed
that GCN5 interacts with C/EBPa WT, C/EBPa 1-207, and
C/EBPa p30/120-358, it failed to interact with C/EBPa
204-358 (Supplementary Fig. 1j). By performing pull-down
assays with FLAG antibody for C/EBPa-TAD1 (Transactivation
domain 1), and C/EBPa-DBD separately, we were unable
to detect any interaction between GCN5 and TAD1 or DBD
domain of C/EBPa (Supplementary Fig. 1k). Collectively, these
observations suggest that the GCN5 interaction domain in C/
EBPa lies in the N-terminal region of C/EBPa (Supplementary
Fig. 1l).
The relevant lysine residues (K298, K302 and K326) were
substituted with arginine to generate non-acetylated mimetic
forms of C/EBPa (referred to as K3R). We further tested whether
a pan-acetyl antibody is able to detect acetylation differences
between C/EBPa WT and K3R or C/EBPa-DBD and
C/EBPa-DBD K3R (Supplementary Fig. 1m). Immunoprecipi-
tated C/EBPa WT or K3R mutant showed no difference in
acetylation using a pan-acetyl antibody, both with (lanes 4 and 5)
and without (lanes 2 and 3) GCN5 co-transfection. In addition,
co-transfection with DBD or DBD K3R did not show any
acetylation signal using a pan-acetyl antibody (lanes 6 and 7).
Immunoprecipitated WT, K3R, DBD, and DBD K3R were
detected by using V5 antibody. These results are in accordance
with our domain-mapping data, suggesting that the C/EBPa DBD
domain does not interact with GCN5, and therefore no
acetylation signal is observed from either DBD or DBD K3R
when co-transfected with GCN5 (Supplementary Fig. 1l).
To detect acetylation of C/EBPa in cells at K298, K302 and
K326, site-specific anti-acetyl-C/EBPa antibodies were generated
using synthetically acetylated peptides. The acetylated and
non-acetylated forms of these peptides were first confirmed by
mass spectrometry. Our antibodies were able to readily recognize
acetylated C/EBPa at K298, K302 and K326. When a
non-acetylated mimetic form of C/EBPa, that is, K3R was used,
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no signal was detected, confirming that the antibodies we
generated are capable of specifically detecting acetylated C/EBPa
(Supplementary Fig. 1n). Consistently, western blotting with
these site-specific acetylation antibodies showed an increase in
acetylated C/EBPa when GCN5 and C/EBPa were co-expressed
in 293T cells (Supplementary Fig. 1o). We also examined whether
K298, K302 and K326 were acetylated in HL-60 and Molm-14,
and the results are consistent when probed with site-specific
antibodies (Fig. 1h). These data indicate that our acetylation-
specific antibodies were able to detect C/EBPa acetylation in the
DBD of C/EBPa.
Loss of C/EBPa acetylation on myeloid differentiation. We
looked at whether endogenous C/EBPa is acetylated at K298, 302
and 326 in vivo and if the acetylation status of C/EBPa changes
with respect to myeloid differentiation. Within the hematopoietic
system, expression of C/EBPa is detectable in early myeloid
precursors and its expression is necessary and sufficient for
neutrophilic differentiation5,19,20. We used non-leukaemic 32Dcl3
cells to assess C/EBPa acetylation status on differentiation. Murine
32Dcl3 cells are dependent on interleukin-3 (IL-3) for survival and
proliferation, and readily differentiate into mature granulocytes on
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Figure 1 | GCN5-mediated acetylation of C/EBPa is linked to loss of transcriptional activity. (a) Western blot analysis with anti-pan-acetyl-lysine
antibody following immunoprecipitation (IP) of C/EBPa with rabbit anti-C/EBPa in HL-60 and Molm-14 human myeloid cell lysates. Rabbit anti-GFP
antibody was used as IP control. (b,c) GCN5 decreases the ability of C/EBPa to transactivate a minimal p(CEBP)4TK promoter in a dose-dependent manner
and is dependent on the GCN5 histone acetyltransferase (HAT) domain. 293T cells were transiently transfected with p(CEBP)4TK, pRL-null, and pcDNA6
expression plasmids for C/EBPa and with GCN5 or GCN5 (-HAT), respectively. Protein expression of corresponding constructs were shown in
Supplementary Fig. 1c. Luciferase activity was measured in duplicate for each experiment and data are shown as mean±s.d. (N¼ 3). (d) Knockdown of
endogenous GCN5 results in an increase in C/EBPa transactivation potential. GCN5 knockdown in 293T cells enhanced C/EBPa transactivation capacity on
a minimal p(CEBP)4TK promoter with pRL-null and pcDNA6 C/EBPa plasmids. Firefly luciferase readings were normalized against internal control renilla
luciferase. Luciferase activity was measured in duplicate for each experiment and data are shown as mean±s.d. (N¼ 3). (e) Western blot demonstrating
knockdown efficiencies of endogenous GCN5 by 3 different shRNAs in 293T cells used in d. (f) GCN5 acetylates C/EBPa at K298, K302 and K326. C/EBPa
peptides were incubated with the GST-HAT domain of GCN5 in the presence of 3H-labeled acetyl-CoA. Tritium incorporation by C/EBPa peptides was
measured by scintillation counting. Error bars represent mean±s.e.m. Experiments were performed twice in duplicate. (g) Structure of the
C/EBPa basic region-leucine zipper domain bound to DNA. Arrows indicate the location of the acetylated lysine residues. (h) Endogenous C/EBPa is
acetylated in the basic leucine zipper region in HL-60 and Molm-14 cells. C/EBPa protein was immunoprecipitated using a rabbit antibody recognizing total
C/EBPa protein, followed by immunoblotting against acetylated C/EBPa antibodies (K298, K302, and K326). Rabbit anti-GFP antibody was used as a
control for IP. **Po0.01 and ***Po0.001; Student’s unpaired t-test (b,d and f).
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FACS and Giemsa-stained cytospins analysis revealed an
efficiency of Z80% in granulocytic differentiation of 32Dcl3
cells on day 4 on G-CSF induction (Supplementary Fig. 2a).
Western blot results showed enrichment of acetylated C/EBPa for
K298 and K302 in 32Dcl3 cells before differentiation by G-CSF is
initiated (Fig. 2a). On G-CSF induction, there was a reduction in
acetylation levels for K298 and K302, which coincides with
the loss of GCN5 protein expression. We then used
acetylation-specific antibodies to determine the endogenous levels
of C/EBPa acetylation in primary acute myeloid leukaemia
(AML) samples in which C/EBPa levels could be detected by
western blot. Undifferentiated human CD34þ cells expressed
such low levels of C/EBPa protein that we were unable to
compare their C/EBPa acetylation signal with AML. Therefore,
we used G-CSF treated CD34þ cells on day 7, in which C/EBPa
protein expression was detected by western blot. C/EBPa was
acetylated at K298 and K302, and GCN5 was higher in AML
samples than in partially differentiated human CD34þ cells
(day 7; Fig. 2b, Supplementary Fig. 2c). We did not observe a
stronger acetylated signal at K302 in AML samples #3, #4 and #5
as compared with other AML samples (Fig. 2b). We were also
unable to detect any signals using acetylated K326-specific
antibody in AML samples and in G-CSF-induced differentiated
32Dcl3 cells (Supplementary Fig. 2b). Our AML sample size was
insufficient to distinguish the difference between K302 acetyla-
tion, and lack of K326 acetylation (Supplementary Table 2). Our
data indicate loss of C/EBPa acetylation at K298 and K302 on
G-CSF-mediated differentiation of murine 32Dcl3 cells. In
addition, C/EBPa acetylation is easily detectable in AML patients
compared with partially differentiated human CD34þ cells.
Interestingly, GCN5 is expressed at higher levels in AML patients
than in normal CD34þ cells (Supplementary Fig. 2d).
Predicting loss of DNA binding for acetylated C/EBPa. On
acetylation, lysine side chains are changed in that the acetyl group
neutralizes the positive charge. Substitution of lysine with
glutamine (neutral side chain) mimics the acetylated form11. To
examine whether glutamine substitution was consistent with
lysine acetylation and to examine the impact of C/EBPa
acetylation on its structure (Fig. 3a), we conducted MD
simulations on four model systems. In addition to the WT
DNA and acetylation mimic (K2Q-DNA) systems, two acetylated
models were also included in this study. The H-N-C¼O dihedral
angle of the acetylated lysine residues was set to 0 and 180 in
the two acetylated models (hereafter termed as K2Ac_a-DNA and
K2Ac_b-DNA, respectively, Fig. 3b; see Computational
methods section for details). The backbone atoms of the four
models showed similar fluctuations during MD simulations
(Supplementary Fig. 3). As compared with the C/EBPa
WT–DNA complex, lysine acetylation (K2Ac_a-DNA and
K2Ac_b-DNA) and acetylation mimic (K2Q-DNA) raised the
calculated protein–DNA-binding free energies substantially
(Table 1). This indicates a decrease in DNA-binding potency of
the models (K2Ac_a-DNA, K2Ac_b-DNA and K2Q-DNA).
According to the crystal structure of C/EBPa WT DNA, one of
the key interactions is formed between K298 and A–5 (ref. 18).
During MD simulations, the three ammonium hydrogen atoms of
K302 formed hydrogen bonds with the phosphate oxygen atoms
of T–4 (Fig. 3c, Supplementary Table 3). The electrostatic
interaction energy between K298 and K302, and DNA residues
T–4 and A–5 is a major component of the total protein–
DNA-binding energy. Both acetylated lysine and glutamine
formed significantly less hydrogen bonds with DNA during the
3 ns MD simulations (Supplementary Table 3). Furthermore, the
electrostatic stabilization between the C/EBPa protein and DNA
residues were significantly lowered in the mutant systems
(Supplementary Table 4). Acetylation might also destabilize the
C/EBPa structure. 15ms MD simulations have shown higher
conformational fluctuations and loss of enzymatic activity both
during acetylation and mutation of K104 to glutamine in RAS23.
Similar structural destabilization might also be responsible for the
loss of C/EBPa transcriptional activity on acetylation.
Acetylation mimetic mutants impairs myeloid differentiation.
To investigate the consequence/s of acetylation on C/EBPa
function, we generated and tested single and various combina-
tions of K298, K302 and K326 sites in which lysine was replaced
with either arginine (hereafter termed as non-acetylated mimetic)























































































































Figure 2 | Loss of C/EBPa acetylation on granulocytic differentiation and
detection in primary AML samples. (a) 32Dcl3 murine IL-3 dependent
cells are differentiated into granulocytes with addition of G-CSF for 4 days.
Western blot analysis showed nuclear extracts using anti acetyl K298,
K302, C/EBPa (D56F10), GCN5, and b-actin antibodies. HL-60 cells and
HL-60 treated with histone deacetylase inhibitors (HDACi: 400 nM
Trichostatin acid (TSA), 20 mM nicotinamide (NA) and 5 mM sodium
butyrate (NB) for 12-16 h before harvest.) were used as a positive control
for C/EBPa specific acetylated antibodies. (b) Enrichment of C/EBPa
acetylation at K298 and K302 in human AML cells compared to partially
differentiated (day 7) human CD34þ cells. Whole-cell lysates were
prepared and blotted with anti-acetyl K298, K302, C/EBPa, GCN5, and
b-actin antibodies, respectively. Non-acetylated mimetic C/EBPa K3R was
used as a negative control while C/EBPa co-transfected with GCN5 was
used as a positive control for acetylation at the respective residues.
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reporter assays. Single acetylation mimetics of all three residues
did not have any major effect on C/EBPa transactivation
(Supplementary Fig. 4a). Interestingly, K298 and K302Q
(C/EBPa-K2Q) and K298, K302 and K326Q (C/EBPa-K3Q)
acetylation mimetic mutation combinations completely abolished
C/EBPa transactivation (Supplementary Fig. 4a,b). Western blots
of the C/EBPa mutations confirmed similar expression levels,
indicating that the loss in reporter activity is not due to reduction
in C/EBPa protein levels (Supplementary Fig. 4a,b). All
corresponding lysine-to-arginine mutations had luciferase activity














































H-N-C=O = 180°H-N-C=O = 0°
Figure 3 | Molecular dynamics simulation of acetylation at K298 and K302. (a) Diagram of the C/EBPa protein. The positions of the three
transactivation elements (TEs), basic region-leucine zipper (BR-LZ) and putative acetylation sites for GCN5 are indicated. (b) The two conformations of the
acetylated lysine (ACK) side chain built into the starting coordinates of the acetylated models and preserved during the MD simulations. (c) MD snapshots
during 3 ns simulation showing selected protein–DNA interactions: I) C/EBPa WT-DNA; II) K2Q-DNA; III) K2Ac_a-DNA; and IV) K2Ac_b-DNA. Hydrogen
bonds are shown as dashed lines.
Table 1 | C/EBPa and DNA interaction energy.
Average s.d. s.e.m.
WT-DNA  84.5 15.7 0.9
K2Q-DNA 43.5 15.1 0.9
K2Ac_a-DNA  68.9 13.3 0.8
K2Ac_b-DNA  56.6 10.9 0.6
s.d., standard deviation; s.e.m., standard error of the mean; WT, wild type.
Calculated MM/PBSA protein–DNA-binding free energies (kcal mol 1) based on 3 ns MD
trajectories.
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acetylation results in the inactivation of C/EBPa function.
To eliminate the possibility of altered conformation and affected
transactivation by clusters of lysine-to-glutamine mutations,
another mutated form (C/EBPa-KIIIQ) was generated to mimic
acetylation of a cluster of three lysine residues (K275, K277 and
K278) located close to the DBD. These three lysine residues were
substituted with glutamine. Although both mutants represented
acetylation mimetic forms, unlike the C/EBPa-K3Q form,
C/EBPa-KIIIQ indeed retained transcriptional activity
(Supplementary Fig. 4b). This strongly argues that retaining the
positive charge is only crucial for the residues in the basic region,
and substituting lysine residues for glutamine does not always
result in loss of function.
The C/EBPa-deficient human cell line K562 was engineered
to conditionally express b-estradiol-inducible constructs to
study how various C/EBPa mutants affect differentiation4.
Without induction, fusion proteins are constitutively expressed
in the cytoplasm, where they are inactive. On induction with
b-estradiol, the fusion protein translocates to the nucleus, where
it is active. Consistent with results from MD simulation and
luciferase assays, cells expressing C/EBPa WT-oestrogen receptor
(ER), C/EBPa K3R-ER and C/EBPa K2R-ER differentiated,
whereas cells expressing ER only, C/EBPa K3Q-ER and C/
EBPa K2Q-ER, remained in an undifferentiated state as assessed
by surface expression of the myeloid marker CD11b, cell
morphology and neutrophilic enzymatic activity (Fig. 4a,b,
Supplementary Fig. 4c–f). Expression levels of the individual
fusion protein in K562 stable clones were assessed by western
blots (Supplementary Fig. 4g). Furthermore, our results showed
that K562 C/EBPa-WT-ER was able to inhibit the increase in cell
numbers within 5 days of culture, as compared with
vector-alone and vehicle (ethanol) control (Supplementary
Fig. 4h). The K562 C/EBPa-K2Q mutant cell line showed an
intermediate inhibition in cell number, which lacked statistically
significant difference (P value¼ 0.148, N¼ 6 with two-way
analysis of variance test; Supplementary Fig. 4h). C/EBPa WT-
ER was able to downregulate endogenous c-Myc as previously
reported by our group whereas C/EBPa-K3Q and C/EBPa K2Q-
ER mutants showed partial downregulation of c-Myc
(Supplementary Fig. 4i)24.
Using a murine model, we further explored whether the
acetylation mimetic form is unable to differentiate progenitors
into mature granulocytic cells. As granulocyte differentiation is
impaired in Cebpafl/fl Mx1-creþ mice, we chose this model to
analyse the differentiation potential of the various C/EBPa
mutants. Ten- to twelve-week-old Cebpafl/fl Mx1-creþ mice and
control (Cebpafl/fl Mx1-cre-) mice were treated with
poly(I:C)1,2,20. Bone marrow was harvested 17–21 days later,
and excision of the Cebpa gene was confirmed by PCR.
Multipotent progenitor LinSca-1þ c-Kitþ (LSK) cells from
CebpaD/D mice were FACS-purified and cultured. Cells were
transduced with retroviruses-expressing green fluorescent protein
(pMSCV IRES GFP, MIG empty vector), WT (C/EBPa-WT), or
mutated forms of C/EBPa (C/EBPa -K3Q and C/EBPa-K3R).
Expression levels of MIG C/EBPa-WT and mutants were assessed
by western blot (Supplementary Fig. 4j). After 7 days of culture,
the percentage of granulocytic differentiation was measured by
Gr-1 and Mac-1 surface staining and by Giemsa stain for
morphological analysis (Fig. 4c,d). The C/EBPa-K3Q acetylation
mimetic mutation was notably unable to form mature
granulocytes. These results suggest that acetylation at K298,
K302 and K326 antagonizes C/EBPa granulocytic differentiation
potential. In addition, acetylation of K298 and K302 alone is
sufficient to impede differentiation.
Further testing of the possibility of GCN5 involvement in
myeloid differentiation was done by using 10–12 weeks old Gcn5
D/DVav-iCreþ and control mice (Gcn5fl/fl)25,26. LSK cells were
FACS-purified and placed in myeloid culture conditions
containing G-CSF. LSK cells from Gcn5 conditional knockout
(Gcn5D/D) produced a 1.7-fold increase in the percentage of
Gr-1þ Mac-1þ cells compared with control mice (Gcn5fl/fl;
Fig. 4e,f; P value¼ 0.0137, N¼ 3, with unpaired two-tailed
Student’s t-test). In conclusion, G-CSF induced in vitro myeloid
differentiation is enhanced in the absence of GCN5.
Acetylation at K298 and K302 reduces DNA-binding ability.
To understand how acetylation of K298 and K302 leads to
C/EBPa inactivation, we assessed changes in homodimerization,
cellular sublocalization and dominant negative function of
the mutant forms over C/EBPa WT. No difference in
homodimerization or localization between C/EBPa WT and
mutated forms was detected (Supplementary Fig. 5a,b). In a
C/EBPa-dependent promoter-luciferase reporter assay,
co-transfection of the C/EBPa-K2Q mutant together with C/EBPa
WT did not show any dominant negative effect by the K2Q
mutant, unlike the C/EBPa p30 form (Supplementary Fig. 5c)27.
Expression of C/EBPa, C/EBPa p30 form, and C/EBPa-K2Q
mutant were confirmed using western blot (Supplementary
Fig. 5d).
To investigate whether acetylation by GCN5 alters C/EBPa
DNA binding in vitro, we performed electrophoretic mobility
shift assays (EMSA). C/EBPa was acetylated by an in vitro
acetyltransferase assay using GCN5 HAT domain protein. EMSA
analysis showed that acetylation of in vitro-translated C/EBPa
reduces its ability to bind to the C/EBPa binding site (Fig. 5a). No
binding was observed in the control lysate. Western blot analysis
of the reaction used for EMSA confirmed C/EBPa acetylation at
K298 and K302 residues (Fig. 5b). MD simulations predicted a
dramatic reduction in the ability of C/EBPa to bind to its target
DNA sequences by the acetylation mimetic C/EBPa-K2Q (Fig. 3c,
Table 1). The DNA-binding abilities of WT and mutated forms of
C/EBPa were also assessed by EMSA, using nuclear extracts from
K562 lines expressing ER empty vector, C/EBPa WT-ER, C/EBPa
K2Q-ER and C/EBPa K2R-ER. As expected, C/EBPa K2Q-ER
extracts demonstrated weakened DNA binding as compared with
C/EBPa WT-ER and C/EBPa K2R-ER. Using anti-C/EBPa
antibody for supershift, we demonstrated specificity of the
C/EBPa-dependent binding in EMSA (Fig. 5c and
Supplementary Fig. 5f). EMSA performed using 293T cells
transfected with C/EBPa K2Q without the ER-tag showed loss
of DNA binding similar to K2Q-ER (Supplementary Fig. 5e,g).
The G-CSF receptor is an important downstream target gene of
C/EBPa, and its promoter region contains C/EBPa-binding
sites28. Minimal recruitment of C/EBPa K2Q-ER to the G-CSF
receptor promoter by chromatin immunoprecipitation (ChIP)
was observed (Fig. 5d). In summary, these results support the
hypothesis that acetylation of these two residues leads to the loss
of DNA-binding activity and subsequent loss of induction of
granulocytic differentiation.
Discussion
In this study, we demonstrated that acetylation on C/EBPa leads
to the loss of differentiation potential. We identified three lysine
residues (K298, K302 and K326) as the acetylation target sites in
C/EBPa by GCN5. With acetylation site-specific antibodies, we
detected acetylation at these three sites in leukaemic cell lines
expressing endogenous C/EBPa. We provided evidence that
C/EBPa acetylation levels and GCN5 expression are reduced on
granulocytic differentiation. Furthermore, we demonstrated
C/EBPa acetylation in primary leukaemic samples. Using
C/EBPa-dependent murine and cellular models, we demonstrated
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Figure 4 | Loss of differentiation potential in acetylation mimetic mutations of C/EBPa. (a,b) C/EBPa K3Q-ER and C/EBPa K2Q-ER fail to upregulate
differentiation marker CD11b in K562 cells. K562 cells were stably transfected with EV-ER, C/EBPa WT-ER, K3Q-ER, K3R-ER, K2R-ER, K2Q-ER, K326R-ER,
or K326Q-ER. Induction of C/EBPa nuclear localization was performed with addition of 5mM b-estradiol. Cells were analysed with FACS for surface
marker CD11b following 4 days of culture. Bar graph shows the percentage of CD11bþ cells, which is indicative of granulocytic differentiation. Data are
mean±s.d. from two independent clones for each construct. ***Po 0.001; Student’s unpaired t-test N¼6 (a) and N¼ 9 (b). (c) C/EBPa-K3Q fails to
differentiate hematopoietic early progenitor cells. LinSca-1þ c-Kitþ (LSK) cells from bone marrow of CebpaD/D mice were transduced with retroviral
expression vectors pMIG EV, C/EBPa-WT, C/EBPa-K3R, and C/EBPa-K3Q to induce differentiation into granulocytes. Cells gated on the GFPþ fraction
were analysed on day 7 for surface markers Gr-1 and Mac-1, indicative of granulocytic differentiation. Data are mean±s.d. ***Po0.001; Student’s unpaired
t-test N¼ 3. (d) Lack of mature granulocytes in C/EBPa-K3Q transduced LSK cells. Cytospins were stained with Wright-Giemsa. Original magnification
x100, scale bars indicate 10mm. The arrows indicate granulocytes with their polymorphonuclear morphology. (e) Increase in myeloid cells on deletion of Gcn5.
LSK cells from Gcn5D/D Vav-iCreþ and control (Gcn5fl/fl) mice were cultured in G-CSF supplemented media. After 7 days, viable cells were assessed
for relative expression of Gr-1 and Mac-1 using flow cytometry. Data shown are representative from four independent experiments done in triplicate.
Data are mean±s.d. *Po0.05; Student’s unpaired t-test. (f) Mature granulocytes morphology from G-CSF induced in vitro culture. Cells were subjected
to Wright-Giemsa staining and pictures were acquired at an original magnification 40. Scale bars indicate 10mm. The arrows indicate granulocytes
with their polymorphonuclear morphology.
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Figure 5 | Acetylation in the basic region impairs DNA binding ability. (a) GCN5 attenuates DNA binding ability of C/EBPa in vitro. EMSA was performed
using a double-stranded C/EBPa binding site oligonucleotide. In vitro-translated C/EBPa was incubated with two separate sources of recombinant
GCN5 (HAT) domain proteins. Co-incubation of ivt C/EBPa with GCN5 (lane 6, 7) resulted in decrease in DNA binding as compared to C/EBPa alone
(lane 4). No binding was observed from ivt. Empty vector (EV) control (lane 2) or from EV incubated with GCN5 (lane 3). Specificity of C/EBPa binding to
the probe was shown by supershift (SS) using C/EBPa antibody (lane 5). (b) Western blot showing in vitro-translated C/EBPa acetylation at K298
and K302 by recombinant GCN5 (HAT domain) protein used in EMSA in a. (c) C/EBPa acetylation mimetic (K2Q-ER) showed reduced DNA binding
affinity in EMSA. Equal amounts of nuclear extracts from K562 lines stably transfected with EV-ER (lanes 2, 3), C/EBPa WT-ER (lanes 4, 5),
C/EBPa K2Q-ER (lane 6, 7), and C/EBPa K2R-ER (lane 8, 9) were used. Cells were treated with 5mM b-estradiol for 45 min. Lane 1 contained probe only.
In lanes 3, 5, 7 and 9, 1mL of a supershifting C/EBPa antibody was added. SS indicates supershifted complex; Shift indicates C/EBPa complex;
and X refers to nonspecific complex observed with this probe. The representative experiment out of three is shown here. (d) Acetylation mimetic form
K2Q was not enriched at a C/EBPa target gene locus G-CSFR27. ChIP analysis of stimulated (45 min) K562 EV-ER, C/EBPa WT-ER, K2Q-ER, and
K2R-ER cells using ER antibody. Fold enrichment is calculated compared to binding to control gene, the inactive involucrin (IVL) locus. Data are mean±s.d.
(N¼ 3). *Po0.05; Student’s unpaired t-test. P value between C/EBPa WT and K2R, K326R, and K326Q is not significant. (e) Model hypothesizing the
effect of C/EBPa acetylation on its function in normal hematopoiesis and leukaemia. Non-acetylated C/EBPa is capable of inducing granulocytic
differentiation. C/EBPa acetylation leads to loss in DNA binding and loss of recruitment to C/EBPa target genes such as the G-CSF receptor, thereby
inhibiting differentiation.
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that the acetylation mimetic forms (K2Q and K3Q) are incapable
of driving granulocytic differentiation in inducible C/EBPa-
dependent assays and in murine primary cells as a result of loss of
DNA binding ability.
This is the first report demonstrating an acetyltransferase that
has repressive activity on C/EBPa function, consistent with the
reciprocal pattern of expression of GCN5 and C/EBPa in HSCs,
in which GCN5 is enriched, while C/EBPa is barely detectable1,29.
Previous studies have described the involvement of multiple
PTMs in modulating C/EBPa30–33. In particular, phosphorylation
of serine 21 has been reported to be clinically relevant during
myeloid differentiation. Hyper-phosphorylation at S21 blocks the
maturation of leukaemic blasts and neutrophilic differentiation
of CD34þ progenitors9,10. Although both acetylation and
phosphorylation impair the ability of C/EBPa to drive
differentiation, the mechanisms of inactivation appear to be
distinct. Acetylation results in a loss of DNA-binding capacity,
while phosphorylation alters conformation of C/EBPa dimers34.
The differential effects of these PTMs on C/EBPa are attributes to
the inherent differences in the chemistry and sites of these
modifications.
Our protein domain mapping data for C/EBPa indicates that
GCN5 docking interaction occurs at the N terminus, whereas
acetylation sites are located at the C terminus in the DBD. Such
observations have been reported in C/EBPa and E2F in which
deletion of the C/EBPa N terminus or the basic region mutation
leads to loss of inhibition of E2F activity4. Several studies have
reported a number of C/EBPa mutations lacking differentiation
potential, some of which are located in the basic region. The
BRM2 (I294A, R297A) mutant protein fails to differentiate cells
into granulocyte and adipocyte lineages. Unlike C/EBPa-K2Q
described in our study, BRM2 does not abrogate DNA
binding17,35. The BR3 (R297G, K298T, R300G, K302N) mutant
contains four substitutions in the basic region. Similar to our
results in C/EBPa-K2Q mutations, although BR3 is also incapable
of binding DNA, protein retains the ability to dimerize36.
However, BR3 was designed on a structural basis, in which
clusters of amino acids within the basic region exhibit a net
positive charge. This differs from C/EBPa-K2Q mutations, which
was selected based on the acetylation sites catalysed by GCN5.
This is consistent with the idea that the C/EBPa-K2R, which
retains a positive charge on these residues, is indistinguishable
from WT C/EBPa in its behaviour in DNA binding and
transactivation. These data show that the positive charge on
K298 and K302 located within the basic region is required for
DNA binding. In fact, our molecular simulation data predicted
that acetylation disrupts the capacity to bind DNA by
neutralizing the positive charge on these lysine residues. It is
important to maintain a positively charged cluster of amino acids
for the interaction with DNA. In agreement with these data and
by using EMSA and ChIP assays, we demonstrated that the
acetylation mimetic mutation (K2Q) is sufficient to decrease
DNA binding. The C/EBPa-K2Q mutant (or acetylated C/EBPa)
lacks DNA binding; however, it does not display dominant
negative function over C/EBPa WT.
In comparison with C/EBPa WT, various mutants differ in the
ability to drive granulocytic differentiation. We focused on the
complete lack of transactivation and/or granulocytic differentiation
consistently observed in K2Q and K3Q mutants of C/EBPa. K326
lies in the dimerization domain of C/EBPa, and substitution with
glutamine (an acetylation mimetic) also prevented differentiation
compared with C/EBPa WT and K326R. Such observations could
also be due to the differences in protein–protein interactions, other
than the homodimerization, which is required for efficient
granulocytic differentiation. Transcription factor Foxo1 acetylation
has been linked to decreased ability to bind DNA, and to become
phosphorylated37. It will be intriguing to examine whether there is
crosstalk between different PTMs on C/EBPa. Furthermore,
substitution of lysine with arginine creates potential new
methylation sites resulting in altered differentiation potential of
mutant C/EBPa. At the very least, substitution of lysine with
glutamine (acetylation mimetic) eliminates the potential for such
self-modification sites.
To investigate the role of GCN5 in hematopoiesis, we crossed
Gcn5fl/fl mice with hematopoietic-specific Vav-iCre. We did not
observe any substantial alteration in myeloid lineage commitment
and differentiation in Gcn5 excised mice (Gcn5 D/DVav-iCreþ ).
However, by testing in vitro granulocytic terminal maturation in a
more refined experiment aimed at analysing the effect of G-CSF
on LSK cells from Gcn5D/DVav-iCreþ , we observed a 1.7-fold
increase in Gr-1þ Mac-1þ cells. The possibility exists that this
model, in which GCN5 was deleted at the earliest stages of
embryonic hematopoietic development, does not represent an
ideal model to study C/EBPa-dependent myeloid commitment
in adult hematopoiesis. We cannot rule out the possibility that
C/EBPa acetylation may be compensated by other HATs. PCAF
shares high homology (88%) with GCN5 in the acetyltransferase
domain, and is reported to be redundant with GCN5 (refs 38–40).
While we did not observe PCAF-mediated repression of C/EBPa
transactivation potential in transient transfection assays,
given these previous reports of redundancy of GCN5 and
PCAF in vivo, future studies involving GCN5 and PCAF double
knockout mice could highlight the role of C/EBPa acetylation in
hematopoietic cells.
GCN5 has been reported to be highly expressed in non-small
cell lung cancer, which correlates with tumour size41. GCN5 also
represses PGC-1a and b transcriptional activity via acetylation in
cultured hepatocytes in mouse liver tissues and in primary
skeletal muscle cells. This acetylation has been linked to changes
in glucose concentration and controls expression of metabolic
genes involved in fatty acid oxidation16,42. C/EBPb is also
reported as a target of GCN5-mediated acetylation during
glucocorticoid stimulated preadipocyte differentiation of 3T3L1
and NIH3T3 cells43. Given the role of C/EBPa in lung
development, glucose metabolism and adipogenesis, it would be
of interest to investigate whether C/EBPa acetylation participates
in these cellular processes in addition to its critical role in
granulocytic differentiation. C/EBPa is inactivated in leukaemia
by diverse molecular mechanisms. In this study, we demonstrated
C/EBPa PTM (acetylation) in primary leukaemia cells, which
may affect its activity. It will be of great interest to investigate
whether the administration of a GCN5 inhibitor represents a
novel therapeutic approach for the treatment of leukaemias.
Methods
Cell Culture. HEK293T (ATCC, CCL11268) cells were maintained in DMEM
(Biowest) supplemented with 10% heat-inactivated FBS (Biowest). BOSC23
(ATTC, CRL11270), HL-60 (ATCC, CCL240), K562 (ATCC, CCL246) and
Molm-14 (kindly provided by Chng Wee Joo, Cancer Science Institute, Singapore)
were maintained in RPMI 1640 supplemented with 10% heat-inactivated FBS
(Biowest). For inhibition of lysine deacetylases, K562 C/EBPa-ER stable cell lines
were maintained in phenol red-free RPMI 1640 supplemented with 10%
charcoal-stripped FBS (Invitrogen). K562, HL-60 and Molm-14 identities were
confirmed by STR profiling (Genetica DNA Laboratories, NC, USA). All cell
lines are tested negative for mycoplasma contamination by MycoAlert PLUS
mycoplasma detection kit (Lonza).
32Dcl3 cells (kindly provided by Motomi Osato, Cancer Science Institute,
Singapore) were maintained in RPMI 1640 supplemented with 10% FBS and IL-3
(5 ng ml 1; PeproTech). Induction of granulocytic differentiation was performed
with removal of IL-3 by three washes with PBS and addition of recombinant
human G-CSF (100 ng ml 1; PeproTech). Cells were harvested for western blot
analysis 4 days post induction.
Bone marrow-derived CD34þ cells (1 106 cells) were obtained from Stem
Cell Technologies and cultured in IMDM (ATCC) supplemented with 10% FBS,
FLT3 ligand (50 ng ml 1), SCF (50 ng ml 1), IL-6 (50 ng ml 1) and G-CSF
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(50 ng ml 1; PeproTech) to induce granulocytic differentiation. IL-6 was replaced
with IL-3 (10 ng ml 1) and G-CSF was reduced to 20 ng ml 1 in the culture media
from day 4 onwards. Fresh media was replenished every 3 days and cells were
harvested on day 7 for western blot analysis.
Patient AML samples. We obtained frozen bone marrow blasts of AML from
patients at the National University Hospital, Singapore. The institutional review
board of the National University of Singapore has approved the study. All patients
provided written informed consent in accordance with the Declaration of Helsinki
Principles. A summary of leukaemia status of the patient samples is described in
Supplementary Table 2.
Plasmid construction. WT 42-kDa human C/EBPa was cloned into the pcDNA6
V5-His-tagged plasmid. All mutations from lysine to either glutamine or arginine
were created by site-directed mutagenesis (Agilent). All mutant constructs created
by PCR were sequence verified. The following C/EBPa mutant expression
constructs were created in the pcDNA6 V5-His backbone: C/EBPa K298Q,
C/EBPa K302Q, C/EBPa K326Q, C/EBPa K298, 302Q (K2Q), C/EBPa K298, 302,
326Q (K3Q), C/EBPa K275, 277, 278Q (KIIIQ), C/EBPa K326R, C/EBPa K298,
302R (K2R) and C/EBPa K298, 302, 326R (K3R). For C/EBPa-ER receptor fusion
protein, the 42-kDa (‘wild-type’) human C/EBPa construct and the respective
C/EBPa mutants were subcloned from pcDNA6 plasmids into the pBabe-ER
plasmid (provided by Alan Friedman, Johns Hopkins University School of
Medicine, Baltimore, USA) digested with BamHI and XhoI, such that they are in
frame with the C-terminal ER ligand-binding domain. Lentiviral shRNAs targeting
GCN5 were purchased from MISSION shRNA at Sigma-Aldrich. For generation of
pMIG-C/EBPa WT and mutant expression constructs, the respective C/EBPa
inserts were subcloned from pcDNA6 plasmids into pMIG plasmid digested with
EcoRI and XhoI. C/EBPa deletion expression constructs were PCR amplified using
pcDNA6 C/EBPa WT V5-His as template and cloned into the pcDNA6 V5-His
plasmid using EcoRI and XhoI. Insert sequences were confirmed by the Sanger
sequencing method.
Luciferase reporter assays. The firefly luciferase reporter gene in the pXP2 vector
is driven by four C/EBP-binding sites derived from G-CSF receptor promoter,
starting from  57 to  37 bp upstream of the major transcription start site of the
G-CSF receptor gene28. As an internal control plasmid for co-transfections, the
pRL-null construct encoding a Renilla luciferase gene (Promega) was used44. Firefly
and Renilla luciferase activities were determined 24 h post transfection with the
dual-luciferase reporter assay system (Promega). Firefly luciferase readings were
normalized against internal control Renilla luciferase and calculated as fold
differences against the activity obtained for the reporter plasmid without C/EBPa
transfection. Luciferase assays were done with p(CEBP)4TK (200 ng), pRL-null
(10 ng), pcDNA6 expression plasmids for C/EBPa (5, 10, 20 or 30 ng), GCN5 or
GCN5 (-HAT) (20, 50, 100, 200 ng) and GCN5 or p300 (1, 5, 20 or 50 ng),
respectively. For GCN5 knockdown effect on C/EBPa transactivation, 100, 500 pg
and 2.5 ng of pcDNA6 C/EBPa plasmid concentrations were used. C/EBPa
acetylation mimetic and non-mimetic mutants luciferase assays were performed
using 500 pg, 1 and 5 ng concentrations of respective pcDNA6 expression plasmids.
Luciferase assays where pcDNA6 C/EBPa K2Q was compared with pcDNA6
C/EBPa K298Q or pcDNA6 C/EBPa K302Q 1, 5 and 50 ng plasmid concentrations
were used (Supplementary Fig. 4a).
In vitro acetylation assay. A GST-tagged GCN5 HAT domain expression con-
struct was provided by Axel Imhof (LMU, Munich, Germany). GST-tagged GCN5
protein was produced and purified from Escherichia coli BL21. GST-tagged
recombinant GCN5 (Catalogue #K311-381G) was also purchased from
SignalChem. In vitro-translated C/EBPa protein was produced in a coupled
transcription and translation rabbit reticulocyte lysate (Promega, Catalogue
#L1170). Peptides were synthesized by first Base (Singapore; Supplementary
Table 1). All peptides were purified by high-performance liquid chromatography to
obtain 495% purity. Substrate peptides were incubated with 0.25 m Ci [3H] acetyl
coenzyme A (Amersham) and 0.1 mg of purified GCN5-GST acetyltransferase
(HAT) domain in a 30 ml acetylation buffer containing 50 mM Tris-HCl (pH 8.0),
50 mM NaCl, 10% glycerol, 0.5 mM EDTA, 1 mM dithiothreitol, 10 mM sodium
buytrate and 1 mM phenylmethylsulfonyl fluoride. Reaction mixtures were
incubated at 30 C for 45 min. Subsequently, the peptides were spotted onto P81
filter paper (Whatman). The filter paper was air-dried and measured for acetylation
activity using liquid scintillation counting.
Mass spectrometric analysis performed on the in vitro acetylated C/EBPa
peptides that cover K298, K302 and K326 lysine residues confirmed acetylation of
these three residues and uncovered an additional acetylation site at K304
(Supplementary Fig. 1e–g). But as acetylation at K304 was not seen in the in vitro
acetyltransferase assay with K304 in overlapping peptides (Supplementary Table 1
for P-7 and P-8; Fig. 1f, Supplementary Fig. 1e–g), no further studies on this lysine
residue were pursued.
Liquid chromatography mass spectrometry analysis. Peptide samples were
analysed using nano-HPLC coupled to an LTQ Velos (Thermo Fisher Scientific).
Peptides were trapped onto a C18 pre-column and separated on an analytical
column using a 1 or 2-h gradient ranging from 2% to 8% acetonitrile/0.1% formic
acid, followed by a 5 min gradient ranging from 8% to 80% acetonitrile/0.1% formic
acid and stayed at 80% acetonitrile/0.1% formic acid for 20 min. MS scans ranged
from 310 to 1,400 m/z, AGC target 3E4, and maximum injection time of 50 ms. The
10 most intense ions with an ion intensity above 1,000 and a charge state excluding
one were sequentially isolated to a maximum AGC target value of 4E4 for a
maximal 100 ms and fragmented by Electron Transfer Dissociation (ETD). The
following parameters were employed for ETD: the reagent ion source temperature
of 160C, reagent ion source emission current of 50 mA, reagent ion source electron
energy of  70.00 V, reagent ion source chemical ionisation of 20 p.s.i., reagent vial
1 ion time of 50, reagent vial 1 AGC target of 1E5, reagent vial 2 ion time of 50,
reagent vial 2 AGC target of 1E5, supplemental activation energy of 15. A dynamic
exclusion list was applied using an exclusion list size of 500, one repeat count,
repeat duration of 45 s, exclusion duration of 30 s as well as a mass width of 1.0 low
and 1.5 high. Expiration count was disabled.
Data processing and database search. Raw file processing for the peptide
samples was carried out using Mascot Daemon (version 2.3.2, Matrix Science).
Data import filter for precursor masses was from 700 to 4,000 Da, with a minimum
scan per group of 1 and a minimum peak count of 10. Mascot search was
performed using the custom made database consisting of three peptide sequences
only: RLRKRVEQLSRC, IAVRKSRDKAKQRC and RKSRDKAKQRNVEC.
No enzyme cleavage was specified. Acetyl (C), Acetyl (K), Acetyl (N-term),
Acetyl (S), Oxidation (M) were set as variable modifications. Tolerance for the
precursor masses was 2 Da and for fragments 0.8 Da. The highest score of MS/MS
spectrum for each intact unique acetylated peptide (with a minimum mascot score
of 25) was manually validated.
Generation of site-specific acetylation antibodies. Acetylation-specific C/EBPa
antisera was raised in rabbits against keyhole limpet haemocyanin (KLH)-
conjugated peptides, which comprised of the following residues of human C/EBPa:
IAVRKAcSRDKAKQR (Ac-K298 antiserum), IAVRKSRDKAcAKQR(Ac-K302
antiserum) and RLRKAcRVEQLSR (Ac-K326 antiserum), with a C-terminal
cysteine residue added to the peptide sequence. Addition of cysteine was for the
conjugation of the synthetic peptide to the carrier protein KLH. Antisera were
purified by binding to acetylated peptide-conjugated Sulfolink gel (Pierce) and
subsequently passed through an additional non-acetylated peptide-conjugated
Sulfolink gel to eliminate non-acetylation-specific antibodies. Purified acetylation-
specific antibodies were used at a dilution of 1:1,000 for western blotting.
Immunoblotting and Immunoprecipitation. For whole-cell lysis, 1 107 cells
were lysed with radioimmunoprecipitation assay buffer. For subcellular
fractionation, nuclear and cytosolic fractions were prepared using Nuclear Extract
Kit from Active Motif. Protein concentrations were quantitated with Biorad
Protein Assay. Proteins were separated on 10% SDS-PAGE gels. Immunoblots were
incubated with primary antibody (Supplementary Table 5) overnight at 4 C,
followed by a secondary horseradish peroxidase-conjugated antibody at room
temperature for 1 h.
For immunoprecipitation of C/EBPa, 800mg of whole cell lysate was used.
radioimmunoprecipitation assay buffer was diluted four times and used as
immunoprecipitation buffer with antibody. Lysate was pre-cleared with rabbit IgG
antibody (Cell Signaling Technology) and Dynabeads Protein A (Invitrogen), while
antibody for immunoprecipitation was bound to Dynabeads Protein A for 1 h at
4 C. Subsequently, the pre-cleared lysate was incubated with the beads-bound
antibody for 3 h with constant rotation at 4 C. Beads-bound immunoprecipitates
were washed thrice with immunoprecipitation buffer. Co-immunoprecipiation of
FLAG-tagged proteins with M2 agarose beads (Sigma) was performed according to
manufacturer’s instructions. Briefly, 1 mg of whole cell lysate was lysed in lysis
buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) and
incubated with anti-FLAG M2 agarose beads overnight at 4 C. Beads-bound
immunoprecipitates were washed thrice with TBS.
Proteins were eluted from the beads under acidic conditions with 0.1 M glycine,
pH 2.3 at room temperature for 5 min with constant shaking. Elutant was
neutralized with 1/10 volume of 0.5 M Tris, pH 7.4 with 1.5 M NaCl and analysed
with immunoblotting.
Computational methods. The crystal structure of the C/EBPa-DNA complex
(known as C/EBPa WT-DNA) was downloaded from the Protein Data Bank (PDB
code: 1NWQ)18. To generate the coordinates for the acetylation mimetic C/EBPa-
K2Q complexed with DNA (K2Q-DNA), K298 and K302 residues were replaced
with glutamine using the UCSF Chimera package45. The GLN rotamers from the
Dunbrack library were used46. The acetylated lysine residues (K2Ac) were built
manually with UCSF Chimera. The H–N–C¼O dihedral angle of all four
acetylated lysine residues were set to 0 in the first acetylated model (hereafter
termed as K2Ac_a-DNA) based on the most populated structures derived from
computations47. However, the acetylated lysine residues in recently published
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crystal structures were found to have the H–N–C¼O dihedral angles with both 0
and 180 (Fig. 3b)48–50. Thus, the H–N–C¼O dihedral angle of all four acetylated
lysine residues were set to 180 in the second acetylated model (K2Ac_b-DNA).
The backbone atoms of the four models showed similar fluctuations during the
3.2 ns long MD simulations (Supplementary Fig. 3). However, longer MD
trajectories are needed to meaningfully discuss the stability of the four models. The
scope of the current computational study is to gain insight into how different
mutations affect protein–DNA-binding energy and protein-DNA hydrogen
bonding. For this purpose, the relatively short MD trajectories presented here
should be sufficient51. The ff03 molecular mechanics (MM) force field was assigned
for all residues52. The acetylation of partial charges derived for use with the ff03
force field were taken from literature with corresponding atom names and atom
types47.The force field parameters were set up using the leap programme of the
AmberTools13 package53. Naþ counterions were added to neutralize the
protein–DNA model systems. The crystallographic water molecules were retained
in all four model systems. Each protein–DNA model complex was placed into a
pre-equilibrated TIP3P truncated octahedral water box54. The crystallographic
water molecules were included in the TIP3P solvent boxes which extended at least
12 Å from the protein-DNA complex.
MM minimizations and MD simulations were carried out with the sander
programme of the AMBER12 package53.The MD simulations were preceded by
three minimization steps: (1) solute atoms were held fixed while solvent molecules
were relaxed (1000 steps of steepest descent and 1,000 steps of conjugate gradient
minimization); (2) solvent atoms were held fixed while solute molecules were
relaxed (1,000 steps of steepest descent and 1,000 steps of conjugate gradient
minimization); (3) both solvent and solute were optimized without any restraints
(1,000 steps of steepest descent and 4000 steps of conjugate gradient
minimization). After minimization, a two-step MD simulation was carried out on
all systems with a 2 kcal mol 1 Å2 restraint on the solute atoms: (1) each system
was heated from 0 to 300 K over a period of 50 ps in the canonical (NVT)
ensemble; (2) each system was relaxed for 50 ps in the isothermic-isobaric (NPT)
ensemble (T¼ 300 K and P¼ 1 atm). Finally, production MD simulations were run
for 3.2 ns in the NPT ensemble (T¼ 300 K and P¼ 1 atm). Force calculations were
performed with periodic boundary conditions and a 9 Å cutoff was used for
non-bonded interactions. Covalent bonds connecting hydrogen atoms were
constrained with SHAKE55. A collision frequency of 3 ps–1 was used in the
Langevin thermostat to maintain the system temperature56. A timestep of 2 fs was
used in all MD simulations. Atom coordinates were saved every 10 ps during the
MD simulations (100 frames ns 1). The random number generator seed was
altered at every restart of the MD simulations.
The polar desolvation free energy was calculated with the MMPBSA.py
program57. The last 3 ns of the MD trajectories were used for Molecular
Mechanics/PoissonBoltzmann Surface Area (MM/PBSA) calculations and
hydrogen bond analysis. The radii optimized by Tan et al.58 were used with a 0.5 Å
grid spacing, a 1.4 Å solvent probe radius, a protein dielectric constant of 1.0, and a
solvent dielectric constant of 80. Due to the expensive computational demand,
entropies were not considered. MM/PBSA calculations can yield satisfactory results
without the inclusion of entropy59.
Generation of stable K562 cell lines. To generate WT or mutant C/EBPa lines,
K562 cells were stably transfected by electroporation with the respective
pBabe-C/EBPa-ER fusion constructs. Briefly, 2 106 cells were electroporated in
an Amaxa apparatus with 5 mg of Sca-1 linearized plasmid. At 48 h post-
transfection, cells were subjected to selection with 0.5 mg ml 1 puromycin and 50
cells were seeded per 96-well plate. C/EBPa-ER nuclear translocation was induced
by addition of 5 mM of b-estradiol (Sigma, E2758). Cells were assessed 4 days post
induction for differentiation by CD11b surface marker expression, morphology and
neutrophilic enzymatic activity4. Multiple individual clones for each type of mutant
were picked and analysed by western blot to confirm expression of the fusion
protein. The results from two representative clones are presented in this study.
Assessment of granulocytic differentiation. Nitroblue tetrazolium analysis with
2.5 105 cells was done as previously described4. The percentage of nitroblue
tetrazolium-positive cells was quantified by counting at least 100 cells for each
mutant under brightfield microscopy (Nikon). Cell morphology was assessed by
Wright-Giemsa staining. Cytospin preparation of 2.5 105 cells were done as
previously described60. For staining of CD11b surface marker, 1 106 cells were
stained with CD11b antibody (Supplementary Table 6) and analysed using LSRII
flow cytometry (BD Biosciences). The resulting data were processed with FlowJo
Version 7.6.4 software (TreeStar).
shRNA lentivirus packaging and transduction. Lentiviral plasmids
(pLKO.1-puro) encoding GCN5-specific shRNA (TRCN0000038879 (shGCN5 #1),
TRCN0000294386 (shGCN5 #2), TRCN0000307319 (shGCN5 #3)) and non-
targeting control shRNA (SHC0002 (NTC #1), SHC007 (NTC #2)) were purchased
from Sigma MISSION. Lentivirus packaging was performed in 293T cells by
co-transfecting shRNA lentiviral plasmids with pCMV-dR8.91and pCMV-VSVG
using Lipofectamine 2000. For GCN5 knockdown, cells were exposed to viral
particles with multiplicities of infection (MOI) ranging from 1 to 2, in the presence
of 8 mg ml 1 polybrene (Santa Cruz) for 24 h. Cells were selected in media
containing 1 mg ml 1 puromycin (Sigma) at 48 h post transduction, and checked
for knockdown efficiency by immunoblotting at 2 weeks post transduction.
Retroviral transduction of CebpaD/D LSK cells. Animal work was done at NUS
with approval from IACUC. C/EBPa conditional knockout (Cebpafl/fl) and
Mx1-Cre mice have been described previously2.
Liquid culture of GCN5 LSK cells. Animal work was done at NUS with approval
from IACUC. Gcn5 D/DVav-iCre knockout mice were generated by crossing Gcn5
fl/fl and Vav-iCre mice25,26. Cells (5,000–10,000) were added to grow in Stemline II
hematopoietic stem cell expansion medium (Sigma-Aldrich) supplemented with
1 Penicillin-Streptomycin, 1 anti-mycotic cocktail, 6 ng ml 1 IL-3,
10 ng ml 1 IL-6, 20 ng ml 1 stem cell factor (SCF), 20 ng ml 1 G-CSF and
10% FBS. Cells were grown for 7 days before proceeding with FACS and
morphological analysis.
Electrophoretic mobility shift assay. EMSA was done as previously described4.
Briefly, EMSA was performed with nuclear extracts from K562 C/EBPa lines.
The oligonucleotides used are derived from the G-CSF receptor promoter
( 57 to  38 bp), the sequences are as follows (C/EBP binding sites are
underlined): upper strand, 50-CTAGGGCTTGCGCAATCTATATTCG-30 , lower
stand, 50-CGAATATAGATTGCGCAAGCCCTA-30 . EMSAs were performed by
incubating 10mg of nuclear extracts with 50,000 counts per minute double-
stranded oligonucleotides in a 25 ml reaction mixture containing 10 mM
HEPES-KOH buffer (pH7.9), 50 mM KCl, 2.5 mM MgCl2, 1 mM DTT, 10%
glycerol, 1 mg bovine serum albumin (BSA) and 0.5 mg poly(dI-dC) on ice for
20 min. For supershift assay, 2 mg of anti-C/EBPa antibody (14AA) or anti-ER
(HC-20) was added to the binding reaction. Binding reactions were resolved on a
6% non-denaturing polyacrylamide gel with 0.5TBE (0.089 M Tris borate and
0.002 M EDTA) and electrophoresed at 140 V at 4 C.
Chromatin immunoprecipitation. ChIP was performed with 2 mg anti-ER
antibodies on K562 C/EBPa-ER cells (2 107 cells). Briefly, cells were induced
with 5 mM b-estradiol for 45 min, fixed in 1% formaldehyde for 5 min at room
temperature and subsequently quenched with addition of glycine to a final
concentration of 200 mM. Cells were lysed with Buffer L1 (50 mM Tris pH 8.0,
2 mM EDTA, 0.1% NP-40, 10% glycerol) for 5 min on ice, centrifuged for 10 min at
850 g. The nuclear pellet was resuspended in Buffer L2 (50 mM Tris pH 8.0,
5 mM EDTA, 1% SDS). Crosslinked chromatin was sonicated using Bioruptor
(Diagenode) at ‘high’ amplitude, 12 s on/30 s off for 16 cycles, and centrifuged for
10 min at 17,000g. Sonicated material was diluted with 9 volumes of Buffer DB
(50 mM Tris, 200 mM NaCl, 5 mM EDTA, 0.5% NP-40) and pre-cleared with
salmon sperm DNA (Sigma), rabbit IgG (Santa Cruz) and Dynabeads Protein A
(Invitrogen). Pre-cleared chromatin was immunoprecipitated overnight with ERa
(HC-20) antibody, followed by addition of Dynabeads Protein A for 30 min at 4 C.
Beads were washed thrice with washing buffer (WB) (20 mM Tris pH 8.0, 500 mM
NaCl, 2 mM EDTA, 0.1% SDS and 1% NP-40), once with WB plus 500 mM LiCl,
thrice with buffer TE. Bound chromatin was eluted from the beads with 100 ml
of elution buffer (1x TE, 2% SDS). After reverse-crosslinking with RNase A and
proteinase K digestion, DNA was purified by Qiaquick PCR purification kit and
eluted with 50ml of TE buffer. Primers used are indicated in Supplementary
Table 7. qPCR was carried out with GoTaq qPCR master mix (Promega) and
analysed with a Corbett Rotorgene system. Relative enrichment is calculated over
the inactive involucrin locus.
Dimerization assay. 293T cells were co-transfected with 10 mg of V5-tagged WT
or mutant versions of C/EBPa and 10mg of FLAG-tagged WT C/EBPa, cell lysates
were collected 24 h after transfection. Anti-FLAG M2 Affinity gel (Sigma) was used
to co-immunoprecipitate FLAG-tagged proteins. Samples were kept under constant
rotation for 2 h at 4 C. Beads-bound immunoprecipitates were washed thrice with
TBS buffer and eluted in SDS-PAGE sample buffer for immunoblotting analysis.
Gene expression analysis. Raw microarray gene expression data (CEL files) for
AML and normal BM CD34þ samples were taken from GSE13159 (ref. 61) and
GSE19429 (ref. 62), respectively. We used the RMA model to extract the gene
intensity from multiple probe intensities, while the cross-array data normalization
was performed using the Cross-Correlation method63.
Statistical analysis. The two-tailed, Student’s t-test was used to compare between
two groups. Asterisk (*) indicates P valueo0.05, ** indicates P valueo0.01,
*** indicates P valueo0.001 in the figures.
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